Single brand, fully-covered, self-expandable metal stent for the treatment of benign biliary disease: When should stents be removed?

Benedetto Mangiavillano, Mouen Khashab, Leonardo H. Eusebi, Ilaria Taratarantino, Mario Bianchetti, Rossella Semeraro, Rinaldo Pellicano, Mario Traina, Alessandro Repici

Research output: Contribution to journalReview article

Abstract

The two most relevant endoscopic treatable benign biliary diseases (BBD) are benign biliary strictures (BBSs) and biliary leaks (BLs), often associated with high morbidity. The most common endoscopic treatment for biliary strictures involves placement of multiple plastic stents (PSs), with or without balloon dilation, followed by planned exchange of the stents. Thus, there continues to be high interest in pursuing alternative endoscopic approaches that may achieve better results with fewer interventions. In this setting, the use of a fully-covered, self-expandable metal stent (FCSE MS) is an attractive alternative to single or multiple PSs for the treatment of BBDs. A single metal stent can remain in place for a longer period of time before removal; however, the maximum time the stent can be remain in place is still not well defined. The aim of this review is to determine the removal time of the TaeWoong® FCSE MS, placed for BBD. According to our data analysis, considering the absence of loss of the covering of the FCSE MS and of any adverse events during and after stent removal, leaving the TaeWoong medical FCSE MS in situ for an 8 months' period seems to be acceptable for benign biliary diseases. Further studies need to evaluate their removability at 1 year.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalMinerva Gastroenterologica e Dietologica
Volume65
Issue number1
DOIs
StatePublished - Mar 1 2019

Fingerprint

Stents
Plastics
Pathologic Constriction
Self Expandable Metallic Stents
Dilatation
Metals
Morbidity

Keywords

  • Cholangiopancreatography
  • Endoscopic retrograde
  • Gallbladder diseases
  • Stents

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Gastroenterology

Cite this

Single brand, fully-covered, self-expandable metal stent for the treatment of benign biliary disease : When should stents be removed? / Mangiavillano, Benedetto; Khashab, Mouen; Eusebi, Leonardo H.; Taratarantino, Ilaria; Bianchetti, Mario; Semeraro, Rossella; Pellicano, Rinaldo; Traina, Mario; Repici, Alessandro.

In: Minerva Gastroenterologica e Dietologica, Vol. 65, No. 1, 01.03.2019, p. 63-69.

Research output: Contribution to journalReview article

Mangiavillano, Benedetto ; Khashab, Mouen ; Eusebi, Leonardo H. ; Taratarantino, Ilaria ; Bianchetti, Mario ; Semeraro, Rossella ; Pellicano, Rinaldo ; Traina, Mario ; Repici, Alessandro. / Single brand, fully-covered, self-expandable metal stent for the treatment of benign biliary disease : When should stents be removed?. In: Minerva Gastroenterologica e Dietologica. 2019 ; Vol. 65, No. 1. pp. 63-69.
@article{0f86ce5c321a468ea9805edb6ca317db,
title = "Single brand, fully-covered, self-expandable metal stent for the treatment of benign biliary disease: When should stents be removed?",
abstract = "The two most relevant endoscopic treatable benign biliary diseases (BBD) are benign biliary strictures (BBSs) and biliary leaks (BLs), often associated with high morbidity. The most common endoscopic treatment for biliary strictures involves placement of multiple plastic stents (PSs), with or without balloon dilation, followed by planned exchange of the stents. Thus, there continues to be high interest in pursuing alternative endoscopic approaches that may achieve better results with fewer interventions. In this setting, the use of a fully-covered, self-expandable metal stent (FCSE MS) is an attractive alternative to single or multiple PSs for the treatment of BBDs. A single metal stent can remain in place for a longer period of time before removal; however, the maximum time the stent can be remain in place is still not well defined. The aim of this review is to determine the removal time of the TaeWoong{\circledR} FCSE MS, placed for BBD. According to our data analysis, considering the absence of loss of the covering of the FCSE MS and of any adverse events during and after stent removal, leaving the TaeWoong medical FCSE MS in situ for an 8 months' period seems to be acceptable for benign biliary diseases. Further studies need to evaluate their removability at 1 year.",
keywords = "Cholangiopancreatography, Endoscopic retrograde, Gallbladder diseases, Stents",
author = "Benedetto Mangiavillano and Mouen Khashab and Eusebi, {Leonardo H.} and Ilaria Taratarantino and Mario Bianchetti and Rossella Semeraro and Rinaldo Pellicano and Mario Traina and Alessandro Repici",
year = "2019",
month = "3",
day = "1",
doi = "10.23736/S1121-421X.18.02506-0",
language = "English (US)",
volume = "65",
pages = "63--69",
journal = "Minerva Gastroenterologica",
issn = "1121-421X",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Single brand, fully-covered, self-expandable metal stent for the treatment of benign biliary disease

T2 - When should stents be removed?

AU - Mangiavillano, Benedetto

AU - Khashab, Mouen

AU - Eusebi, Leonardo H.

AU - Taratarantino, Ilaria

AU - Bianchetti, Mario

AU - Semeraro, Rossella

AU - Pellicano, Rinaldo

AU - Traina, Mario

AU - Repici, Alessandro

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The two most relevant endoscopic treatable benign biliary diseases (BBD) are benign biliary strictures (BBSs) and biliary leaks (BLs), often associated with high morbidity. The most common endoscopic treatment for biliary strictures involves placement of multiple plastic stents (PSs), with or without balloon dilation, followed by planned exchange of the stents. Thus, there continues to be high interest in pursuing alternative endoscopic approaches that may achieve better results with fewer interventions. In this setting, the use of a fully-covered, self-expandable metal stent (FCSE MS) is an attractive alternative to single or multiple PSs for the treatment of BBDs. A single metal stent can remain in place for a longer period of time before removal; however, the maximum time the stent can be remain in place is still not well defined. The aim of this review is to determine the removal time of the TaeWoong® FCSE MS, placed for BBD. According to our data analysis, considering the absence of loss of the covering of the FCSE MS and of any adverse events during and after stent removal, leaving the TaeWoong medical FCSE MS in situ for an 8 months' period seems to be acceptable for benign biliary diseases. Further studies need to evaluate their removability at 1 year.

AB - The two most relevant endoscopic treatable benign biliary diseases (BBD) are benign biliary strictures (BBSs) and biliary leaks (BLs), often associated with high morbidity. The most common endoscopic treatment for biliary strictures involves placement of multiple plastic stents (PSs), with or without balloon dilation, followed by planned exchange of the stents. Thus, there continues to be high interest in pursuing alternative endoscopic approaches that may achieve better results with fewer interventions. In this setting, the use of a fully-covered, self-expandable metal stent (FCSE MS) is an attractive alternative to single or multiple PSs for the treatment of BBDs. A single metal stent can remain in place for a longer period of time before removal; however, the maximum time the stent can be remain in place is still not well defined. The aim of this review is to determine the removal time of the TaeWoong® FCSE MS, placed for BBD. According to our data analysis, considering the absence of loss of the covering of the FCSE MS and of any adverse events during and after stent removal, leaving the TaeWoong medical FCSE MS in situ for an 8 months' period seems to be acceptable for benign biliary diseases. Further studies need to evaluate their removability at 1 year.

KW - Cholangiopancreatography

KW - Endoscopic retrograde

KW - Gallbladder diseases

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=85060367191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060367191&partnerID=8YFLogxK

U2 - 10.23736/S1121-421X.18.02506-0

DO - 10.23736/S1121-421X.18.02506-0

M3 - Review article

C2 - 29856174

AN - SCOPUS:85060367191

VL - 65

SP - 63

EP - 69

JO - Minerva Gastroenterologica

JF - Minerva Gastroenterologica

SN - 1121-421X

IS - 1

ER -